Amgen and Biosimilars: What the Biotech Giant Gets Right — and Where It Gets Tested
Amgen built its empire on one idea: biologics are the future of medicine. But here's the thing about biologics — they don't stay protected forever. In real terms, markets open. And drugs like Humira, Enbrel, and Remicade generated billions in annual revenue and turned Amgen into one of the most valuable biotech companies on the planet. For decades, that bet paid off beautifully. Patents expire. And biosimilars come knocking.
So what happens when the company that pioneered blockbuster biologics now has to compete with cheaper copies of its own drugs? That's the question at the heart of evaluating Amgen on biosimilars. And honestly, the answer is more nuanced than most people realize Easy to understand, harder to ignore..
What Is Amgen's Role in the Biosimilars Landscape
The Innovator Problem
Amgen is, at its core, an innovator company. Humira — a treatment for autoimmune conditions like rheumatoid arthritis and Crohn's disease — was one of the best-selling drugs in human history. Enbrel did the same for autoimmune and inflammatory conditions. Because of that, that means it developed the original versions of some of the most prescribed biologic drugs in the world. Remicade tackled everything from plaque psoriasis to ulcerative colitis Worth keeping that in mind..
These drugs are now facing (or have already faced) biosimilar competition. A biosimilar is not a generic drug — it's a biologic that's highly similar to an already-approved reference product, with no clinically meaningful differences in safety, purity, and potency. In real terms, because biologics are complex molecules made from living cells, you can't just copy them exactly the way you would a small-molecule generic. That's why they're called "biosimilars," not "generics That's the whole idea..
Real talk — this step gets skipped all the time.
Amgen's Own Biosimilar Portfolio
Here's where it gets interesting. Still, amgen isn't just sitting on the sidelines watching biosimilars eat into its revenue. Plus, the company has actively entered the biosimilar market itself. Amjevita (adalimumab-atto) was Amgen's first approved biosimilar to Humira, launching in the U.But s. Here's the thing — in 2016. It was developed through a partnership with Samsung Bioepis, and it gave Amgen a foothold in the growing biosimilar space It's one of those things that adds up..
Since then, Amgen has expanded its biosimilar pipeline. The company has products targeting reference drugs beyond just Humira, including biosimilars to other major biologics. Amgen's strategy here is clear: if you can't beat the biosimilar wave, ride it. By developing its own biosimilars, Amgen positions itself to capture market share in the very segments where its originator drugs are losing exclusivity Most people skip this — try not to..
The Business Model Shift
Evaluating Amgen on biosimilars means understanding that the company is essentially running two different business models simultaneously. On one hand, it's still an innovator pushing novel biologics through the pipeline — things like newer antibody therapies and cell-based treatments. Alternatively, it's becoming a player in the value-driven biosimilar market, where pricing pressure is intense and margins are thinner Turns out it matters..
That dual identity creates both opportunity and risk. And it's worth unpacking both.
Why This Matters for Investors and the Industry
Revenue Erosion Is Real
When a blockbuster biologic loses patent protection, the revenue hit can be staggering. That's why analysts have estimated that Humira alone could lose billions in annual sales as biosimilars capture market share. For Amgen, which has historically depended heavily on its immunology portfolio, this erosion is not theoretical — it's already happening.
Biosimilars typically launch at 15% to 30% below the reference product's price, and that discount tends to grow over time as competition increases. For Amgen's originator drugs, this means pricing power erodes and market share shifts. Understanding how Amgen manages this transition tells you a lot about the company's long-term resilience Worth keeping that in mind..
Biosimilars Are a Growth Engine
On the flip side, the global biosimilar market is projected to grow substantially over the next decade. Day to day, estimates vary, but many analysts see the market reaching $50 billion or more by the early 2030s. For a company like Amgen with the scientific infrastructure, regulatory expertise, and manufacturing capability to produce biosimilars at scale, this represents a genuine growth opportunity.
Easier said than done, but still worth knowing.
Amgen's partnership model — particularly with Samsung Bioepis — also matters. Collaborations allow the company to share development costs and risks while still gaining access to commercial revenue. That's a smart move in an industry where the cost of bringing a biosimilar to market can run into the hundreds of millions of dollars.
The Payer and Physician Perspective
Biosimilars aren't just a story about money — they're about access. When biosimilars enter the market, they give insurers and health systems more options, which can lower costs for patients and governments. Amgen's role in this dynamic is complicated. Here's the thing — as the originator company, it has an incentive to protect its market share. But as a biosimilar maker, it benefits from the broader adoption of biosimilar products Still holds up..
This tension is something evaluators need to keep in mind. Amgen's incentives aren't always aligned with the pure biosimilar movement, and that creates strategic questions about how aggressively the company pushes its own biosimilar products versus its originators.
How Amgen's Biosimilar Strategy Actually Works
The Samsung Bioepis Partnership
The Samsung Bioepis collaboration has been central to Amgen's biosimilar ambitions. Under this partnership, Samsung Bioepis handles much of the early development and manufacturing, while Amgen contributes its deep knowledge of immunology, clinical development, and commercialization. The companies share profits, and Amgen gets to focus on the areas where it has the most expertise.
This model has worked well for Amjevita, which has gained traction in markets where Humira's patent protections have lapsed. It's also been extended to other biosimilar candidates, giving Amgen a diversified pipeline without requiring the company to build out every capability from scratch.
Targeting Multiple Reference Products
Amgen isn't putting all its biosimilar eggs in one basket. The company has developed or is developing biosimilars targeting several different reference products, not just Humira. This diversification helps protect against the risk that a single biosimilar market doesn't develop as expected or that competitive dynamics shift in an unexpected way Surprisingly effective..
People argue about this. Here's where I land on it.
Take this: Amgen has biosimilar candidates targeting other TNF-alpha inhibitors and other classes of biologics used in autoimmune diseases, oncology, and ophthalmology. The broader the portfolio, the more resilient the business becomes as the market evolves Most people skip this — try not to..
Regulatory and Manufacturing Expertise
One advantage Amgen has over smaller biotech companies entering the biosimilar space is its regulatory track record. The FDA and EMA have stringent requirements for biosimilar approval,
Regulatory and Manufacturing Expertise
The FDA and EMA have stringent requirements for biosimilar approval, demanding dependable comparability studies, extensive analytical characterization, and well‑designed clinical trials that demonstrate no clinically meaningful differences from the reference product. On the flip side, amgen’s long‑standing experience with biologics—having navigated dozens of complex INDs, Phase何, and post‑marketing commitments—means it can design and execute these studies with precision. In practice, its manufacturing facilities, many of which are certified to GMP standards for high‑volume biologic production, allow it to scale quickly once regulatory hurdles are cleared. This dual advantage reduces the time‑to‑market and the financial risk that smaller competitors often face when building new bioreactors or hiring specialized regulatory teams Not complicated — just consistent..
Navigating Market Acceptance
Even with regulatory clearance, biosimilars must win the confidence of prescribers, payers, and patients. In the United States, the FDA’s interchangeability designation requires a rigorous set of pharmacokinetic and pharmacodynamic data. Amgen’s biosimilars have already been granted interchangeability for a few key products, lending credence to its portfolio and encouraging pharmacy benefit managers to include them in formularies. In real terms, amgen cause‑makes a concerted effort to demonstrate interchangeability in jurisdictions where it is permitted, thereby allowing pharmacists to substitute the biosimilar automatically. Beyond that, Amgen’s marketing teams, accustomed to launching complex biologics, are adept at highlighting the safety, efficacy, and cost‑effectiveness of their biosimilars through evidence‑based education and real‑world data.
Competition and Pricing Dynamics
The biosimilar market is becoming increasingly crowded, with a growing number of entrants from both established pharma and newer biotech firms. Practically speaking, amgen’s strategy to partner with Samsung Bioepis—who offers a strong manufacturing base in Asia—helps keep production costs lower, enabling more aggressive pricing strategies. Also, pricing pressures are intense; payers are now demanding discounts that can erode margins. At the same time, Amgen’s originator products, such as EYLEA and Amjevita, continue to command premium prices in niche indications, providing a financial cushion that can support the biosimilar line.
Strategic Flexibility and Future Outlook
Amgen’s biosimilar approach is not a single‑product focus. The company is also exploring “next‑generation” biologics, such as biosimilars of antibody‑drug conjugates and engineered biologics, where the regulatory pathway may be similar but the commercial potential higher. By diversifying across several therapeutic areas—rheumatology, oncology, ophthalmology, and more—it mitigates the risk that a particular market segment stalls. In doing so, Amgen positions itself to capture a larger share of the biologics value chain, from discovery through commercialization.
Conclusion
Amgen’s dual role as both originator and biosimilar developer presents a unique opportunity to balance innovation with cost‑efficiency. In real terms, by leveraging its deep scientific expertise, regulatory pedigree, and large‑scale manufacturing capabilities—while simultaneously partnering with Samsung Bioepis to share risk and resources—Amgen is carving out a resilient biosimilar portfolio. The company’s ability to work through pricing pressures, secure interchangeability where possible, and diversify across multiple indications will determine how well it can sustain growth in a rapidly evolving market. At the end of the day, Amgen’s biosimilar strategy illustrates a pragmatic path forward: harnessing the strengths of an established pharmaceutical behemoth to lower costs and broaden access, without sacrificing the rigorous standards that safeguard patient safety and therapeutic efficacy Took long enough..
Quick note before moving on.
